RDEA3170 and Febuxostat Drug Interaction Study

Phase 1 Completed 21 enrolled Ardea Biosciences, Inc.

RandomizedCrossoverDouble-blindBasic science

Summary

This study will evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD) interaction between the XO inhibitor febuxostat and the investigational URAT1 inhibitor RDEA3170 and provide information for potential future clinical studies using this combination. Combination treatment using 2 drugs with different mechanisms of action may achieve improved response and may allow the use of lower doses, resulting in fewer side effects than the use of either drug alone.

Timeline

Start: 2013-06
Primary completion: 2013-09
Completion: 2013-12

Publications

Rekic D, Johansson S, Leander J. Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight. Clin Pharmacokinet. 2021 Mar;60(3):319-328. doi: 10.1007/s40262-020-00943-6. Epub 2020 Sep 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Febuxostat	Small molecule	40 mg	Oral
Subject	Verinurad	Small molecule	10 mg	—

Indications

No indication recorded.